ProCE Banner Activity

Paid Activity

CE

Muscular Dystrophy: Causes, Symptoms and Treatment Options

Video

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Released: November 26, 2022

Expiration: November 26, 2024

Course Fee

$30.00

Share

Additional Information

Program Medium

This program has been made available online.

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.


 

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities?
 

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.

The term Muscular dystrophy refers to a group of inherited and incurable disorders that result in progressive muscle weakness and atrophy. There are nine major forms of muscular dystrophy causing different genetic mutations affecting different gender, age, and muscle groups. With some types of muscular disorder, patients can have significant disability with early onset of death while other forms will allow patients to live into adulthood and have minimal disability. This activity will review the nine different types of muscular dystrophy, their clinical presentation and prognosis. It also focuses on available pharmacologic treatment options as well as examples of those in clinical trials. The activity also highlights the importance of the required multidisciplinary approach for the management of these patients.

Target Audience

The target audience for this activity includes pharmacists and nurses.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the epidemiology, risk factors, and pathology of Muscular Dystrophy.
  • Discuss the screening, diagnosis, and types for Muscular Dystrophy.
  • Outline treatment regimens for Muscular Dystrophy and future pipeline of treatments.
  • Discuss multidisciplinary strategies in management of muscular dystrophy.

Faculty

Mitra Habibi, PharmD
Clinical Associate Professor
Neuroscience Clinical Pharmacist
Departments of Pharmacy Practice & Neurology
University of Illinois at Chicago

CME/CE Accreditation

Release Date: November 26, 2021
Expiration Date: November 26, 2024

 

ACPE Credit Designation (Pharmacist CE) This CE activity is jointly provided by ProCE, LLC and the National Association of Specialty Pharmacy (NASP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-271-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 0.75 contact hours (0.075 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Fees are required for this activity.
 


Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.
 

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Mitra Habibi, PharmD, has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Emily Shafer, PharmD, has no relevant conflicts of interest to report.
Robin Wanous-Williamson (nurse planner) has no relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Emily Shafer, PharmD.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Funding

Provided by ProCE, LLC in partnership with the National Association of Specialty Pharmacy (NASP).

This continuing education activity is supported by an educational grant from AllianceRx Walgreens Prime. 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.